Founder Michael Yocco, a South Whidbey resident, draws on his biochemistry background to develop lotions and creams for pain ...
New long‑term clinical data show that TREMFYA® (guselkumab), an IL‑23 inhibitor, is the first treatment of its kind to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback